Turna Ray
Turna Ray has been covering the personalized medicine and molecular diagnostics industries for GenomeWeb since 2006. She closely tracks the evolving regulatory, reimbursement, and business environment for precision medicine products.
Articles Authored by Turna Ray
Genetic Testing Challenges in Precision Medicine: Ataxia Patient Tested for Cardiomyopathy Genes
A neurologist orders the wrong genetic test for a patient experiencing peripheral neuropathy and doesn't realize it even upon seeing the report.
Genetic Testing Challenges in Precision Medicine: Li-Fraumeni Diagnosis Missed in Young Patient
A 31-year-old woman with stage IV breast cancer learns a test ordered more than a year before her diagnosis detected a TP53 mutation but she wasn't told.
Researchers analyzed molecular and particulate matter exposure data on nearly 9,000 NSCLC patients in France and confirmed a link reported by UK scientists in 2022.
'Vast Majority' of Cancer Patients Lack Access to Essential Drugs Despite Advances, Says WHO Expert
Premium
Using Herceptin as an example, Andre Ilbawi detailed the challenges low- and medium-income countries face in accessing essential therapies.
Genetic Testing Challenges in Precision Medicine: Parents' Tragedy After Wrong Tay-Sachs Test Order
A physician orders targeted HEXA sequencing when full sequencing is warranted during a high-risk couple's preconception screening, leading to dire consequences.
Very Few Patients Eligible for Tissue-Agnostic TRK Inhibitors Get Them, Real-World Analysis Shows
Premium
Data presented at ASCO found that only a dozen out of 800 patients with NTRK-altered advanced solid tumors got Vitrakvi or Rozlytrek over a two-year period.
Breast Cancer Patients With VUS Generally Not Overtreated, Real-World Data Analysis Suggests
Premium
A study drawing on germline genetic testing and claims data showed at ASCO that patients with VUS are, for the most part, managed like they have negative results.
In UK Biobank data, researchers found that clonal hematopoiesis of indeterminate potential exacerbates the impact of air pollution in non-smokers with lung cancer.
Merck's Keytruda Sales Increase 20 Percent in Q1
For the first three months of the year, the company's worldwide sales grew 9 percent to $15.78 billion and beat the consensus Wall Street revenue expectation.
At AACR's annual meeting, industry observers discussed how FDA's stance on RUOs amid its push to regulate LDTs is putting the "double squeeze" on the lab industry.